Document is current
Any future updates will be listed below
-
Authors
Scott, Andrew J. https://orcid.org/0000-0002-0835-4888
Mittal, Anjali https://orcid.org/0000-0001-5670-032X
Meghdadi, Baharan https://orcid.org/0000-0001-8871-1488
O’Brien, Alexandra
Bailleul, Justine
Sravya, Palavalasa
Achreja, Abhinav https://orcid.org/0000-0002-1773-6490
Zhou, Weihua https://orcid.org/0000-0003-0259-0828
Xu, Jie
Lin, Angelica
Wilder-Romans, Kari
Liang, Ningning https://orcid.org/0000-0003-1439-7929
Kothari, Ayesha U.
Korimerla, Navyateja
Edwards, Donna M.
Wu, Zhe
Feng, Jiane
Su, Sophia
Zhang, Li
Sajjakulnukit, Peter https://orcid.org/0000-0002-8556-7481
Andren, Anthony C.
Park, Junyoung O. https://orcid.org/0000-0001-9869-8993
ten Hoeve, Johanna https://orcid.org/0000-0003-0226-749X
Tarnal, Vijay https://orcid.org/0000-0002-2795-1610
Redic, Kimberly A.
Qi, Nathan R. https://orcid.org/0000-0003-1919-9171
Fischer, Joshua L.
Yang, Ethan
Regan, Michael S. https://orcid.org/0000-0001-5252-2829
Stopka, Sylwia A.
Baquer, Gerard
Suresh, Krithika
Sarkaria, Jann N.
Lawrence, Theodore S.
Venneti, Sriram
Agar, Nathalie Y. R. https://orcid.org/0000-0003-3149-3146
Vlashi, Erina
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Al-Holou, Wajd N. https://orcid.org/0000-0001-8528-4855
Nagrath, Deepak https://orcid.org/0000-0002-8999-2282
Wahl, Daniel R. https://orcid.org/0000-0001-9894-5085
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 28 July 2025
First Online: 3 September 2025
Competing interests
: D.R.W. has consulted for Agios Pharmaceuticals, Admare Pharmaceuticals, Bruker and Innocrin Pharmaceuticals. D.R.W. is listed as an inventor on patents pertaining to the treatment of patients with brain tumours (US provisional patent application 63/416,146, US provisional patent application 62/744,342, US provisional patent application 62/724,337). A.J.S., D.N., C.A.L., A.M., A.A. and B.M. are listed as co-inventors on US provisional patent application 63/416,146. N.Y.R.A. reports the following disclosures: key opinion leader to Bruker Daltonics, collaboration with Thermo Finnigan, service agreement with EMD Serono, service agreement with iTeos Therapeutics, and founder and board member of BondZ. In the past three years, C.A.L. has consulted for Odyssey Therapeutics and Third Rock Ventures. W.N.A.-H. has consulted for Servier Pharmaceuticals. The other authors declare no competing interests.
